Mersana Therapeutics (MRSN) Receives a Buy from TD Cowen
In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report). The company’s ...
Mersana Therapeutics, Inc.: Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug ...
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on ...
Hosted on MSN7d
William Blair Initiates Coverage of Mersana Therapeutics (MRSN) with Outperform Recommendation
Fintel reports that on February 6, 2025, William Blair initiated coverage of Mersana Therapeutics (NasdaqGS:MRSN) with a ...
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
JP Morgan analyst Samik Chatterjee initiated coverage on Jamf Holding Corp. JAMF with an Overweight rating and announced a ...
Mersana Therapeutics initiated with an Outperform at William Blair
William Blair analyst Andy Hsieh last night initiated coverage of Mersana Therapeutics (MRSN) with an Outperform rating. The firm believes ...
Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) ...
Investing23d
Mersana Therapeutics Inc (MRSN)
This page features the latest news about the Mersana Therapeutics stock. MRSN stock touches 52-week low at $0.56 amid market challenges Mersana Therapeutics Inc . (NASDAQ:MRSN) stock has reached a ...
MRSN stock touches 52-week low at $0.56 amid market challenges
Mersana Therapeutics Inc . (NASDAQ:MRSN) stock has reached a new 52-week low, trading at $0.56, as the biopharmaceutical company faces a challenging market environment. According to InvestingPro data, ...